What is the appropriate evaluation and management for abdominal itching in a pregnant patient?

Evaluation and Management of Abdominal Itching in Pregnancy

Initial Assessment

For a pregnant patient with abdominal itching, immediately assess for the presence or absence of a rash, as this fundamentally determines the diagnostic pathway and urgency of evaluation. 1

Key History Elements

When evaluating pruritus in pregnancy, obtain specific details about: 1

• Timing of onset (second vs. third trimester) and whether itching is worse at night
• Location (generalized, palms/soles, abdomen, or striae)
• Presence of rash (papules, plaques, vesicles, bullae, or only excoriations from scratching)
• Associated symptoms (jaundice, dark urine, excessive fatigue, abdominal pain)
• History of atopy (eczema, allergic rhinitis, asthma)
• Previous pregnancy complications (prior intrahepatic cholestasis of pregnancy)
• Medications (particularly opioids, hydrochlorothiazide)
• Risk factors for hepatitis (IV drug use, sexual history)

Physical Examination Findings

The physical exam should specifically identify: 1

• Rash characteristics and distribution (face, trunk, abdomen, striae, periumbilical area)
• Excoriations (may be the only skin finding in intrahepatic cholestasis of pregnancy)
• Jaundice or scleral icterus (suggests hepatic disease beyond typical intrahepatic cholestasis of pregnancy)
• Dark urine (uncommon in intrahepatic cholestasis of pregnancy)

Differential Diagnosis

Pruritus WITHOUT Rash (Most Concerning)

Intrahepatic cholestasis of pregnancy (ICP) is the most critical diagnosis to exclude when pruritus occurs without a primary rash, as it carries significant fetal risks including stillbirth. 1

ICP typically presents with: 1

• Generalized itching predominantly affecting palms and soles
• Worse at night
• Onset in second or third trimester (most commonly third trimester)
• No primary rash (only excoriations from scratching)

Pruritus WITH Rash (Generally Lower Fetal Risk)

When a primary rash is present, consider these pregnancy-specific dermatoses: 1

• Atopic eruption of pregnancy (AEP) - most common pruritic disorder; eczematous rash on face, neck, flexural areas, trunk
• Polymorphic eruption of pregnancy (PEP) - most common dermatosis; urticarial papules and plaques on abdomen and thighs, spares the umbilicus, often appears in striae distensae 1, 2
• Pemphigoid gestationis (PG) - rare; vesicles and bullae with periumbilical involvement 1, 2

Laboratory Evaluation

For Suspected Intrahepatic Cholestasis of Pregnancy

Order total serum bile acid levels immediately when ICP is suspected; this is the diagnostic test of choice. 1

The diagnosis of ICP requires total serum bile acid level >10 μmol/L in the setting of pruritus during the second or third trimester. 1

Additional testing should include: 1

• Serum AST and ALT (typically elevated 10-20 times upper limit of normal)
• Total bilirubin (usually <6 mg/dL; higher levels suggest alternative diagnosis)
• Alkaline phosphatase (mild elevations are normal in pregnancy)

If initial bile acid levels are normal but clinical suspicion remains high, repeat testing after excluding other causes of pruritus. 1

Bile Acid Testing Methods

Two assay types are available: 1

• Mass spectrometry/liquid chromatography (4-14 day turnaround; provides fractionated levels)
• Enzymatic assay (4 hours to 4 days turnaround; provides total bile acids only)

The enzymatic assay is clinically sufficient, as total bile acid level is the most clinically useful value for risk stratification and management decisions. 1

Exclude Other Causes

When bile acids are normal, evaluate for: 1

• Biliary obstruction
• Viral hepatitis (hepatitis B and C serology)
• Chronic liver disease
• Thyroid dysfunction
• Renal disease
• Hematologic malignancies
• HIV infection

Management

For Intrahepatic Cholestasis of Pregnancy

Initiate treatment with ursodeoxycholic acid at a total daily dose of 10-15 mg/kg/day in divided doses. 1

Ursodeoxycholic acid has been shown to: 1

• Improve pruritus symptoms
• Reduce serum bile acid and ALT levels
• Decrease adverse outcomes including preterm birth and stillbirth (per recent meta-analysis)

Additional antipruritic options if ursodeoxycholic acid alone is insufficient: 1

• Cholestyramine
• Rifampicin

Delivery Timing Based on Bile Acid Levels

Delivery timing should be determined by total serum bile acid levels, as these correlate directly with risk of intrauterine fetal demise: 1

• Bile acids >100 μmol/L: Deliver at 36 weeks or at diagnosis if after 36 weeks (highest stillbirth risk after 35 weeks) 1
• Bile acids <100 μmol/L: Deliver at 36-39 weeks depending on when diagnosed 1
• Bile acids <40 μmol/L: Consider delivery at term with individualized management 1

For Pregnancy-Specific Dermatoses (With Rash)

Management depends on the specific diagnosis: 3, 4

• Topical emollients for all cases
• Topical corticosteroids for localized pruritus
• Systemic corticosteroids for severe cases (pemphigoid gestationis)
• Antihistamines (restricted number are safe in pregnancy) for generalized pruritus
• UV phototherapy for generalized pruritus when appropriate

Note that pemphigoid gestationis, like ICP, is associated with fetal risks including prematurity and stillbirth, requiring close monitoring. 3

Follow-Up

Pruritus from ICP typically resolves after delivery; if it persists beyond 6 weeks postpartum, pursue evaluation for underlying chronic liver disease. 1

Critical Pitfalls to Avoid

• Do not dismiss pruritus without rash as "normal pregnancy itching" - this presentation mandates bile acid testing to exclude ICP 1
• Do not delay bile acid testing - fetal risk increases with higher bile acid levels, particularly >100 μmol/L 1
• Do not confuse excoriations from scratching with a primary rash - ICP patients may have significant skin changes from scratching that can be mistaken for a dermatosis 1
• Do not assume normal initial bile acids exclude ICP - repeat testing if clinical suspicion remains high 1